Handen 2000.

Methods	Cross‐over trial of 0.3 mg/kg methylphenidate, 0.6 mg/kg methylphenidate or placebo
Participants	Inclusion criteria: while off all psychotropic medication score of ≥ 30 on a parent‐completed CARS diagnosis of autism or PDD‐NOS made by a board‐certified child psychiatrist score of ≥ 15 points on the Hyperactivity Index of the Teacher Conners' Rating Scale Exclusion criteria: not reported Location/setting: participants were recruited from either special education programmes, a psychiatric inpatient unit, or intensive day‐treatment programme. Sample size: 13 in total (cross‐over) Number of withdrawals/dropouts: 1 person was not included in the analysis; however, reasons were not provided. Gender: 10 male participants, 3 female participants Mean age: median 7.4 years IQ: 3 had severe/profound disability, 5 had moderate intellectual disability, 4 had mild intellectual disability, 1 had average IQ Baseline ABC‐I or other BoC: not reported Concomitant medications: not reported History of previous medications: not reported
Interventions	Intervention 1 (0.3 mg/kg methylphenidate for 7 days): 0.3 mg/kg doses of methylphenidate rounded to the nearest 2.5 mg was given 2‐3 times/day for 7 consecutive days. Doses were given at breakfast and 4 h later with lunch. Intervention 2 (0.6 mg methylphenidate for 7 days): 0.6 mg/kg doses of methylphenidate rounded to the nearest 2.5 mg was given 2‐3 times/day for 7 consecutive days. Doses were given at breakfast and 4 h later with lunch. Comparator (placebo for 7 days): equivalent placebo doses
Outcomes	Primary outcomes: irritability, measured using the ABC‐I subscale (Aman 1985) AEs Secondary outcomes: not reported Timing of outcome assessment: not reported
Notes	Study start date: not reported Study end date: not reported Source of funding: "This research was supported by a grant to the third author from the Fanny Pushin Rosenberg Research Foundation." Conflicts of interest: none declared